Ann: Antisense Therapeutics transitions to new Board Chair, page-97

26 May 2021
Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD• Manufacture of ATL1102 active pharmaceutical ingredient (API) batch completed

This formulated injectable product (Drug Product or DP) is currently undergoing finished product release testing for clinical use, with results anticipated later next month.

Mark Diamond CEO of Antisense Therapeutics said: “We are very pleased with how the manufacture of clinical supplies for our planned Phase IIb trial of ATL1102 has proceeded particularly given the challenges that have presented to all CMO’s during the global covid pandemic.



The above are some paragraphs taken from the Ann dated 26/5/2021. To note:
- batch completed
- injectable product results anticipated later next month. Meaning max end June 2021
- Diamond mentioning is very pleased on how the manufacturing…….has proceeded.

Unless I have missed something nothing of the above had any follow up. Is it another of the usual splendid
P.R. skill from ANP leader?
One pip up or down a day may not mean anything but m.d.
professional (?) activity doesn’t help to impress the market.